BIOMAT Database Logo BIOMAT Database Logo

[Use of I-131-meta-iodobenzylguanidine in the treatment of malignant pheochromocytoma. Description of 2 cases]. 1986

W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D019797 3-Iodobenzylguanidine A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase. (3-Iodo-(131I)benzyl)guanidine,Iobenguane,MIBG,3-Iodobenzylguanidine, 123I Labeled,3-Iodobenzylguanidine, 125I Labeled,Iobenguane (131I),m-Iodobenzylguanidine,meta-Iodobenzylguanidine,123I Labeled 3-Iodobenzylguanidine,125I Labeled 3-Iodobenzylguanidine,3 Iodobenzylguanidine,3 Iodobenzylguanidine, 123I Labeled,3 Iodobenzylguanidine, 125I Labeled,m Iodobenzylguanidine,meta Iodobenzylguanidine

Related Publications

W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
131-I-meta-iodobenzylguanidine in treatment of malignant phaeochromocytomas.
July 1983, Lancet (London, England),
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
131-I-meta-iodobenzylguanidine for the diagnosis and treatment of pheochromocytoma.
January 1988, Panminerva medica,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
[131-iodine meta-iodobenzylguanidine scintigraphy and therapy in malignant pheochromocytoma].
January 1986, Der Internist,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
[Clinical remission and reduction of malignant pheochromocytoma treated with iodine-131-meta-iodobenzylguanidine].
November 1996, Medicina clinica,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
February 2023, Endocrine-related cancer,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine.
February 1991, Cancer,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma.
February 1991, The Journal of clinical endocrinology and metabolism,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
Side effects of treatment with I-131-meta-iodobenzylguanidine (I-131-MIBG) in neuroblastoma patients.
January 1988, Progress in clinical and biological research,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
[Treatment of malignant pheochromocytoma by 131-I-metaiodobenzylguanidine].
January 1988, Annales d'endocrinologie,
W Jakubowski, and T Feltynowski, and J Woy-Wojciechowski, and E Leowska, and A Liziniewicz
[Scintigraphy using I 131 iodobenzylguanidine and malignant melanomas].
October 1990, Nederlands tijdschrift voor geneeskunde,
Copied contents to your clipboard!